Movement Alert｜Luye Pharma Rises 6.45% in Regular Trading, Convertible Bond Redemption and Positive Clinical Data Drive Three-Day Rally

Market Focus07-15

On July 15, Luye Pharma rose 6.45% in regular trading, reaching HK$2.27 per share with turnover of HK$71.38 million, marking its third consecutive day of gains.

The rally is driven by multiple catalysts. The company completed early redemption of all outstanding US$180 million 6.25% convertible bonds due 2028 on July 6, with all bonds redeemed and cancelled, effectively eliminating potential equity dilution pressure. Concurrently, Luye issued new US$180 million 5.25% convertible bonds due 2031, successfully refinancing its debt and reducing financing costs by 100 basis points.

Additionally, the company's self-developed innovative drug LY03015, a first-in-class VMAT2 inhibitor and Sigma-1R agonist for tardive dyskinesia, achieved positive Phase II results in China, meeting its primary endpoint. The highest dose group demonstrated a 76.5% response rate, nearly double historical data for existing first-line drugs. The company plans to advance into Phase III trials in both China and the U.S. Zhangshang Securities maintains a Strong Buy rating on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167855685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167855685","market":"us","top_or_hot":-1,"title":"Movement Alert｜Luye Pharma Rises 6.45% in Regular Trading, Convertible Bond Redemption and Positive Clinical Data Drive Three-Day Rally","media":"Market Focus","content":"<p><p>On July 15, Luye Pharma rose 6.45% in regular trading, reaching HK$2.27 per share with turnover of HK$71.38 million, marking its third consecutive day of gains.</p><p>The rally is driven by multiple catalysts. The company completed early redemption of all outstanding US$180 million 6.25% convertible bonds due 2028 on July 6, with all bonds redeemed and cancelled, effectively eliminating potential equity dilution pressure. Concurrently, Luye issued new US$180 million 5.25% convertible bonds due 2031, successfully refinancing its debt and reducing financing costs by 100 basis points.</p><p>Additionally, the company's self-developed innovative drug LY03015, a first-in-class VMAT2 inhibitor and Sigma-1R agonist for tardive dyskinesia, achieved positive Phase II results in China, meeting its primary endpoint. The highest dose group demonstrated a 76.5% response rate, nearly double historical data for existing first-line drugs. The company plans to advance into Phase III trials in both China and the U.S. Zhangshang Securities maintains a Strong Buy rating on the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Luye Pharma Rises 6.45% in Regular Trading, Convertible Bond Redemption and Positive Clinical Data Drive Three-Day Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Luye Pharma Rises 6.45% in Regular Trading, Convertible Bond Redemption and Positive Clinical Data Drive Three-Day Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Luye Pharma rose 6.45% in regular trading, reaching HK$2.27 per share with turnover of HK$71.38 million, marking its third consecutive day of gains.</p><p>The rally is driven by multiple catalysts. The company completed early redemption of all outstanding US$180 million 6.25% convertible bonds due 2028 on July 6, with all bonds redeemed and cancelled, effectively eliminating potential equity dilution pressure. Concurrently, Luye issued new US$180 million 5.25% convertible bonds due 2031, successfully refinancing its debt and reducing financing costs by 100 basis points.</p><p>Additionally, the company's self-developed innovative drug LY03015, a first-in-class VMAT2 inhibitor and Sigma-1R agonist for tardive dyskinesia, achieved positive Phase II results in China, meeting its primary endpoint. The highest dose group demonstrated a 76.5% response rate, nearly double historical data for existing first-line drugs. The company plans to advance into Phase III trials in both China and the U.S. Zhangshang Securities maintains a Strong Buy rating on the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02186","symbol_name":"绿叶制药","start_time":0,"source_url":"","article_id":"1167855685","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167855685","pubTimestamp":1784080177,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Luye Pharma rose 6.45% in regular trading, reaching HK$2.27 per share with turnover of HK$71.38 million, marking its third consecutive day of gains.The rally is driven by multiple...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02186":"绿叶制药"},"translate_title":"走势提醒|绿叶制药常规交易上涨6.45%，可转债赎回和积极的临床数据推动三日反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1},"content_text":"On July 15, Luye Pharma rose 6.45% in regular trading, reaching HK$2.27 per share with turnover of HK$71.38 million, marking its third consecutive day of gains.The rally is driven by multiple catalysts. The company completed early redemption of all outstanding US$180 million 6.25% convertible bonds due 2028 on July 6, with all bonds redeemed and cancelled, effectively eliminating potential equity dilution pressure. Concurrently, Luye issued new US$180 million 5.25% convertible bonds due 2031, successfully refinancing its debt and reducing financing costs by 100 basis points.Additionally, the company's self-developed innovative drug LY03015, a first-in-class VMAT2 inhibitor and Sigma-1R agonist for tardive dyskinesia, achieved positive Phase II results in China, meeting its primary endpoint. The highest dose group demonstrated a 76.5% response rate, nearly double historical data for existing first-line drugs. The company plans to advance into Phase III trials in both China and the U.S. Zhangshang Securities maintains a Strong Buy rating on the stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167855685","isCrawlerRequest":true}